<DOC>
	<DOCNO>NCT01072630</DOCNO>
	<brief_summary>The primary objective study determine whether armodafinil treatment , dosage 150 mg/day , effective placebo treatment adjunctive therapy mood stabilizer treatment adult major depression associate bipolar I disorder .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Armodafinil Treatment Adjunctive Therapy Adults With Major Depression Associated With Bipolar I Disorder</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>The patient diagnosis bipolar I disorder accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion currently experience major depressive episode . Documentation patient least 1 previous manic mixed episode . The patient 6 mood episode last year . The patient 's current major depressive episode must start less 2 week 12 month prior screen visit . The current depressive episode must begin patient 's current mood stabilizer regime begin . The patient must take 1 ( 2 ) follow protocolallowed mood stabilizer : lithium , valproic acid , lamotrigine , aripiprazole , olanzapine , risperidone , ziprasidone ( take combination lithium valproic acid ) . Written inform consent obtain . The patient man woman 18 65 year age . The patient good health ( except diagnosis bipolar I disorder ) judge investigator , basis medical psychiatric history , medical examination , electrocardiography ( ECG ) , serum chemistry , hematology , urinalysis . Women childbearing potential ( woman reach menopause , woman le 2 year postmenopausal , woman surgically sterile ) sexually active must use medically accept method contraception must agree continue use method duration study 30 day participation study . The patient willing able comply study restriction attend regularly schedule clinic visit specify protocol . The patient permanent accommodation mean contacted study center . The patient understands may enroll clinical study may enroll clinical study participate trial . The patient Axis I disorder apart bipolar I disorder primary focus treatment within 6 month screen visit screen period . The patient psychotic symptom psychosis within 4 week screen visit screen period . The patient current active suicidal ideation , imminent risk selfharm , history significant suicidal ideation suicide attempt time past cause concern present . The patient history eat disorder obsessive compulsive disorder ( OCD ) within 6 month screen visit screen period . The patient history alcohol substance abuse dependence ( exception nicotine dependence ) within 3 month screen visit screen period . The patient history cutaneous drug reaction drug hypersensitivity reaction , history clinically significant hypersensitivity reaction , history multiple clinically relevant allergy . The patient clinically significant uncontrolled medical condition , treat untreated . The patient receive modafinil armodafinil within past 5 year , patient know sensitivity ingredient study drug tablet . The patient previously participate clinical study armodafinil use investigational product within 90 day screen . The patient may enroll clinical study participate study . The patient ever treat vagus nerve stimulation ( VNS ) deep brain stimulation ( DBS ) , treat electroconvulsive therapy ( ECT ) repetitive transcranial magnetic stimulation ( rTMS ) within 3 month screen visit . The patient pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Bipolar I Disorder</keyword>
</DOC>